In addition to a greater risk for serious infection, patients with atopic dermatitis initiating JAK inhibitors vs Th2 cytokine inhibitors had a greater risk of Candida infections and a slightly ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

Interest in cytokine modulation has expanded further with the success of interleukin (IL) inhibitors, as well as inhibitors of kinases involved in signalling downstream of cytokine receptors ...

The IL-12 cytokine factories, combined with checkpoint inhibitors, successfully eliminated local and distal tumors in ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

A new implant safely triggers potent immune responses against hard-to-treat cancers showing "promise" for pancreatic and ...

It remains unclear, however, which proportion of this increased risk can be attributed to the use of cytokine inhibitors, to the underlying disease, or to other immunosuppressive medications ...

Cytokines have been the mainstay of treatment ... A large number of new small molecule inhibitors are emerging that have caused considerable interest in the oncology community.

Janus kinase (JAK) inhibitors: tofacitinib, filgotinib and upadacitinib. Cytokine inhibitors: ustekinumab, which targets interleukin (IL) 12, subunit p40/p35; risankizumab, mirikizumab ...